KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Equity Average (2016 - 2025)

NovoCure's Equity Average history spans 11 years, with the latest figure at $340.9 million for Q4 2025.

  • For Q4 2025, Equity Average fell 5.43% year-over-year to $340.9 million; the TTM value through Dec 2025 reached $340.9 million, down 5.43%, while the annual FY2025 figure was $350.3 million, 3.05% down from the prior year.
  • Equity Average for Q4 2025 was $340.9 million at NovoCure, down from $345.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $443.5 million in Q3 2022 and bottomed at $340.9 million in Q4 2025.
  • The 5-year median for Equity Average is $394.7 million (2021), against an average of $393.2 million.
  • The largest annual shift saw Equity Average skyrocketed 84.6% in 2021 before it fell 17.34% in 2024.
  • A 5-year view of Equity Average shows it stood at $411.8 million in 2021, then increased by 7.64% to $443.3 million in 2022, then dropped by 14.71% to $378.1 million in 2023, then decreased by 4.66% to $360.5 million in 2024, then dropped by 5.43% to $340.9 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Equity Average are $340.9 million (Q4 2025), $345.4 million (Q3 2025), and $355.7 million (Q2 2025).